Award for study on Prota’s peanut oral immunotherapy

17 September 2025

Prota Therapeutics, an Australian biotech developing novel oral immunotherapy treatments that induce remission of allergy, has received an award for clinical research conducted in partnership with Murdoch Children’s Research Institute (MCRI) and presented at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress.

The research, which won the EAACI Prize for outstanding oral abstract presentation. reported three-year post-treatment findings from the Phase IIb PPOIT-003 long-term (PPOIT-003LT) study of Prota’s lead candidate, PRT120, a peanut oral immunotherapy with a proprietary short-term dosing regimen designed to induce durable remission.

PRT120 has the potential to offer children and families the freedom to live without the daily fear and treatment burden of peanut allergy

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK